Chinese Innovative Drugs Developer Nets $170M Eyeing High Blood Pressure Treatment

Chinese innovative drugs developer Allist Pharmaceuticals announced on Thursday that it has raised RMB1.18 billion (US$170.75 million) in a new funding round led by healthcare-focused private equity firm Shiyu Capital.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

LEAVE A REPLY